Estamos realizando la búsqueda. Por favor, espere...
1552
37
171
26541
4223
2557
339
Abstract: Mouse transgenesis has provided fundamental insights into pancreatic cancer, but is limited by the long duration of allele/model generation. Here we show transfection-based multiplexed delivery of CRISPR/Cas9 to the pancreas of adult mice, allowing simultaneous editing of multiple gene sets in individual cells. We use the method to induce pancreatic cancer and exploit CRISPR/Cas9 mutational signatures for phylogenetic tracking of metastatic disease. Our results demonstrate that CRISPR/Cas9-multiplexing enables key applications, such as combinatorial gene-network analysis, in vivo synthetic lethality screening and chromosome engineering. Negative-selection screening in the pancreas using multiplexed-CRISPR/Cas9 confirms the vulnerability of pancreatic cells to Brca2-inactivation in a Kras-mutant context. We also demonstrate modelling of chromosomal deletions and targeted somatic engineering of inter-chromosomal translocations, offering multifaceted opportunities to study complex structural variation, a hallmark of pancreatic cancer. The low-frequency mosaic pattern of transfection-based CRISPR/Cas9 delivery faithfully recapitulates the stochastic nature of human tumorigenesis, supporting wide applicability for biological/preclinical research.
Fuente: Nature Communications 7, Article number: 10770 (2016)
Editorial: Nature Publishing Group
Fecha de publicación: 01/02/2016
Nº de páginas: 13
Tipo de publicación: Artículo de Revista
DOI: 10.1038/ncomms10770
ISSN: 2041-1723
Consultar en UCrea Leer publicación
MARESCH, ROMAN
MUELLER, SEBASTIAN
VELTKAMP, CHRISTIAN
OLLINGER, RUPERT
FRIEDRICH, MATHIAS
HEID, IRINA
STEIGER, KATJA
WEBER, JULIA
ENGLEITNER, THOMAS
BARENBOIM, MAXIM
KLEIN, SABINE
LOUZADA, SANDRA
BANERJEE, RUBY
STRONG, ALEXANDER
STAUBER, TERESA
GROSS, NINA
GEUMANN, ULF
LANGE, SEBASTIAN
RINGELHAN, MARC
IGNACIO VARELA EGOCHEAGA
Volver